VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Update

VYNE Therapeutics Inc. (NASDAQ:VYNE) saw a significant increase in short interest in the month of June. As of June 15th, there was short interest totalling 62,700 shares, an increase of 22.2% from the May 31st total of 51,300 shares. Based on an average daily volume of 92,100 shares, the short-interest ratio is currently 0.7 days. Approximately 0.5% of the company’s shares are short sold.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $5.75 price objective on shares of VYNE Therapeutics in a report on Friday, June 14th.

VYNE Therapeutics Stock Performance

Shares of NASDAQ VYNE opened at $1.97 on Monday. The firm has a fifty day simple moving average of $2.42 and a two-hundred day simple moving average of $2.35. VYNE Therapeutics has a 12 month low of $1.57 and a 12 month high of $6.79. The firm has a market capitalization of $28.62 million, a PE ratio of -0.36 and a beta of 1.31.

VYNE Therapeutics (NASDAQ:VYNE) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.09. The company had revenue of $0.10 million during the quarter, compared to the consensus estimate of $0.10 million. VYNE Therapeutics had a negative net margin of 6,874.47% and a negative return on equity of 56.75%. On average, sell-side analysts predict that VYNE Therapeutics will post -0.77 earnings per share for the current year.

Institutional Investors Weigh In On VYNE Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in VYNE. Eventide Asset Management LLC bought a new stake in shares of VYNE Therapeutics during the 4th quarter valued at $3,249,000. Parkman Healthcare Partners LLC purchased a new position in VYNE Therapeutics during the 4th quarter valued at about $1,623,000. Finally, Virtu Financial LLC bought a new stake in VYNE Therapeutics during the first quarter worth about $50,000. 83.78% of the stock is owned by hedge funds and other institutional investors.

About VYNE Therapeutics

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.